Clinical trials: Allogeneic Stem-Cell Transplant
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)
The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the severe combined immunodeficiency (SCID) caused by mutations in the human DCLRE1C gene (Artemis) by transplantation of a single dose of…
- Trial name
- ARTEGENE (NCT05071222)
- Testing
- ARTEGENE drug product
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Spinal Cord Injury, Safety
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial
This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
- Conditions
- Spinal Cord Injury, Safety, Clinical Trials, Efficacy
- Trial name
- NCT06976229
- Testing
- Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Graft Versus Host Disease, Graft Vs Host Disease
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have…
- Conditions
- Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy
- Trial name
- NCT07006506
- Testing
- Belumosudil
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Lymphoma
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma
Primary Objectives: 1. To determine the efficacy of administering multiple doses of intravenous (i.v.) busulfan at a dose of 130 mg/m2, to yield a systemic plasma drug exposure represented by a daily area under the plasma…
- Trial name
- NCT00427765
- Testing
- Busulfan, Melphalan
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Diseases
T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
The main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow…
- Trial name
- NCT03531736
- Testing
- Antithymocyte globulin (Rabbit), fludarabine, total body irradiation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Transplantation Candidates With Hematological Diseases
CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA
This is an early-stage, open-label clinical study of CD19-BCMA dual nanobody based CAR-T Cell desensitization therapy for patients positive for Donor-Specific Antibodies.
- Trial name
- NCT07451236
- Testing
- CD19-BCMA dual nanobody based CAR-T Cells
- Volunteers
- 18 people
- Sponsor
- Chang Yingjun
Relapsed Acute Myeloid Leukemia
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient…
- Trial name
- NCT04582864
- Testing
- Flotetuzumab, Donor lymphocyte infusion
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Cancer, Hematological
Pre-Exercise for Allogeneic Stem Cell Transplant Patients
The PRESENT-P study is a one-arm exercise intervention study for hematological cancer patients prior allogeneic stem cell transplantation (allo-HCT).
- Trial name
- PRESENT-P (NCT03080792)
- Testing
- Experimental: moderate to high-intensity exercise
- Where
- 5 sites in Germany
- Volunteers
- 14 people
- Sponsor
- University Hospital Heidelberg
GVHD, Hematologic Neoplasms
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host…
- Trial name
- NCT03680092
- Testing
- Cyclophosphamide, abatacept, Methotrexate
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Dimitrios Tzachanis, MD PhD
Malignant Hematological Diseases
Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
The occurrence of bronchiolitis obliterans syndrome (SBO) after allogeneic hematopoietic stem cell transplantation (HSCT) is considered to be a chronic pulmonary graft versus host disease (GVHD) that is associated with…
- Trial name
- ALLOZITHRO (NCT01959100)
- Testing
- Azithromycin
- Where
- France
- Volunteers
- 480 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
5-day Defibrotide Treatment for Hepatic SOS/VOD
Sinusoidal Obstruction Syndrome (SOS), also referred to as hepatic veno-occlusive disease (VOD), is rare but serious complication of allogeneic stem cell transplantation (allo-SCT).
- Conditions
- Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Bone Marrow Transplant Complications
- Trial name
- NCT04313036
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Loyola University
Graft Versus Host Disease
Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT
Low-dose post-transplant cyclophosphamide have demonstrated therapeutic efficacy in allogeneic stem cell transplants which is comparable with the standard dose and also facilitates early hematological recovery.
- Trial name
- NCT07319000
- Testing
- Cyclophosphamide
- Where
- Mexico
- Volunteers
- 35 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Disorder Related to Bone Marrow Transplantation, Leukemia
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if combining busulfan with clofarabine and fludarabine can help control the disease better than the previous standard method (using busulfan and fludarabine alone) in patients…
- Conditions
- Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
- Trial name
- NCT01471444
- Testing
- Fludarabine, Clofarabine, Busulfan
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancy, Older Patients
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies
- Conditions
- Hematologic Malignancy, Older Patients, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT05084027
- Testing
- venetoclax combining with fludarabine and melphalan
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hematologic Malignancy
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is evaluate the safety and tolerability of MPH966, a neutrophil elastase inhibitor, and its ability to prevent graft-versus-host disease after hematopoietic stem cell transplant.
- Trial name
- NCT03986086
- Testing
- MPH966
- Where
- United States
- Sponsor
- Nelson Chao
Hyperbaric Oxygen Therapy, Acute-graft-versus-host Disease
HBOT in the Treatment and Prevention of aGVHD
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic strategy for patients with hematopoietic malignancies.
- Trial name
- NCT05078073
- Testing
- Hyperbaric oxygen therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shandong Provincial Hospital
Cytomegalovirus Infections
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
Many risk factors are known to be associated with high risk of developing CMV infection in positive CMV-serostatus patients: negative CMV-serostatus donor, unrelated or mismatched donor, use of antithymocyte globulin (ATG), and…
- Trial name
- CMV-GVHD (NCT05370976)
- Testing
- Cytotect®CP
- Where
- France
- Volunteers
- 2 people
- Sponsor
- University Hospital, Lille
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
This phase II trial studies how well T cell depleted donor peripheral blood stem cell transplant works in preventing graft-versus-host disease in younger patients with high risk hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT01858740
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelofibrosis
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)
The only curative treatment for patients with myelofibrosis (MF) is allogeneic stem cell transplantation (SCT). Treatment with JAK2 inhibitors like pacritinib improves condition of MF patients, decreases spleen size and might…
- Trial name
- HOVON134MF (NCT03645824)
- Testing
- Pacritinib
- Where
- 12 sites in Belgium, Netherlands
- Volunteers
- 61 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Leukemia
Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in Patients with Relapsed/refractory Acute Leukemia…
- Trial name
- NCT02784561
- Testing
- Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd), Cytarabine(Actavis Italy S.p.A), Fludarabine (Bayer)
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital